Search Result

Results for "

abnormal kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Aurora Kinase (4) Autophagy (2) Bcr-Abl (2) c-Kit (1) c-Met/HGFR (1) EGFR (1) FGFR (1) Filovirus (1) IGF-1R (1) MAP3K (1) PDGFR (2) Raf (1) RET (1) SphK (1) VEGFR (2) Wee1 (1)
By Research Areas:	Cancer (10) Infection (1) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148066

DB0662	Others	Others
DB0662 is a compound for kinase-targeted protein degradation and can be used in studies of diseases mediated by abnormal kinase activity, as well as for the identification of degradable kinases and optimal kinases .

HY-145601

Tinengotinib TT 00420	Aurora Kinase VEGFR	Cancer
Tinengotinib is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1) .

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-153227

SU 5616	c-Met/HGFR	Cancer
SU 5616 is an organic compound. SU 5616 potentially modulates tyrosine kinase signal transduction, and regulates abnormal cell proliferation .

HY-10971

Alisertib Maximum Cited Publications 43 Publications Verification MLN 8237	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-101837

CGP 53716	Others	Inflammation/Immunology
CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .

HY-152247

DDO3711	MAP3K	Cancer
DDO3711, a PP5-recruiting phosphatase recruitment chimeras (PHORCs), is formed by connecting a small molecular apoptosis signal-regulated kinase 1 (ASK1) inhibitor to a PP5 activator through a chemical linker. DDO3711 specifically inhibits ASK1 (IC₅₀ =164.1 nM) not ASK2 (IC₅₀>20 μM). DDO3711 significantly dephosphorylates p-ASK1 ^T838 by recruiting PP5 and shows the ASK1-dependent antiproliferative activity. DDO3711 has anti-cancer activity and has the potential for abnormally phosphorylated oncoproteins research .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC₅₀=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase .

HY-10971A

Alisertib sodium MLN 8237 sodium	Aurora Kinase Autophagy Apoptosis	Cancer
Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .

HY-21291

SU-4313	PDGFR EGFR IGF-1R	Cancer
SU-4313 is a potent *protein tyrosine kinases* (PTKs) modulator with IC₅₀*s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase* and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation .

HY-161880

WEE1-IN-10	Wee1	Cancer
WEE1-IN-10 (compound 77) is a Wee1 kinase inhibitor. WEE1-IN-10 shows inhibitory activity on LOVO cell growth, with an IC₅₀ of 0.524 μM. WEE1-IN-10 can be used for the research of diseases caused by abnormal activity of Wee1 .

HY-124042

K6PC-5 1 Publications Verification	SphK Filovirus	Infection Neurological Disease Inflammation/Immunology
K6PC-5, a ceramide derivative, is a *sphingosine kinase* 1(SPHK1)** activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research .

HY-W395613

TY-011	Aurora Kinase	Cancer
TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC₅₀ value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library	2,930 compounds
Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR. MCE designs a unique collection of 2,930 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Protein Kinase Compound Library

2,930 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 2,930 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.